1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Substance
  6.  » 
  7. Bioconjugate Development
  8.  » Partnering / Pipeline

Antibody-drug Conjugates & Bioconjugates


Catalent Biologics offers flexible options for our partners to employ SMARTag® technology in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services.

To inquire about possible SMARTag® collaboration opportunities, including partnerships around our proprietary preclinical CD22 and HER2 ADC programs, please click here.